Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Jamaica
(0/week)
Netherlands Antilles
(0/week)
View all
(0/week)
News
United States
(1123/week)
Manufacturing
(540/week)
Energy
(431/week)
Technology
(1037/week)
Other Manufacturing
(333/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Menstruation
Jun 01, 2020
Sumitovant Biopharma Announces Myovant Sciences' Submission of New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
Mar 09, 2020
The global premenstrual syndrome treatment market was valued at $1,129 million in 2018, and is projected to reach $1,516 million by 2026, registering a CAGR of 3.7% from 2019 to 2026
Jan 31, 2020
California AB 1989 Will Allow Manufacturers of Period Care Products to Continue to Hide Ingredients
Jan 29, 2020
Adore Me introduces Joyja - an ultra-inclusive brand of period panties
Dec 04, 2019
Study Finds Key Brain Region Smaller in Birth Control Pill Users
Sep 25, 2019
Aleve® Demonstrates More Pain Relief Than Acetaminophen for Menstrual Cramps, Study Shows
May 20, 2019
Ava Unveils Unprecedented Insights Into Physical Changes During Menstrual Cycle That Can Be Used to Accurately Identify Fertile Window
Oct 08, 2018
Myovant Sciences and Flo Health Partner to Develop Digital Tool to Screen Women for Heavy Menstrual Bleeding
Aug 09, 2018
Global Menstrual Cup (Disposable & Reusable) Market 2018-2022
Jul 10, 2018
Myovant Sciences Announces Completion of Screening for Phase 3 LIBERTY 1 Study Evaluating Relugolix in Women with Uterine Fibroids
Apr 24, 2018
Women's Health Company Hologic and Actor, Director Aisha Tyler Partner to Help the One in Five Women Suffering in Silence with Heavy Periods
Nov 17, 2017
Menstrual Cups Market - Global Industry Analysis, Size, Share, Trends and Forecast, 2015 - 2023
Nov 09, 2017
Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix for the Treatment of Pain Associated with Uterine Fibroids
Oct 02, 2017
Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix Compared with Leuprorelin for the Treatment of Uterine Fibroids
Latest News
Jul 17, 2025
Grid Dynamics Helps SmartRay Create an AI Robotic Inspection Platform in Collaboration with Wandelbots
Jul 17, 2025
Planet Expands Multi-Year Contract with Instituto Geográfico Agustín Codazzi (IGAC), Providing Satellite Data...
Jul 17, 2025
Antenna Group Launches Conscious Compass to Help Brands Navigate the Journey From Purpose to Impact
Jul 17, 2025
Ayar Labs Strengthens Leadership Team and Expands Global Presence to Accelerate High Volume Co-Packaged Optics
Jul 17, 2025
Fortune Brands Sets Date for Second Quarter Earnings Announcement and Investor Conference Call
Jul 17, 2025
CDimension Launches to Tackle Hardware Bottlenecks from the Ground Up, Beginning with Commercial 2D Materials...
Jul 17, 2025
Divert, Inc. and United States Cold Storage Collaborate to Transform Food That Can’t Be Sold or Donated into...
Jul 17, 2025
Wrangler® and STATE Blaze a New Trail for Back-to-School
View all News
Agenda
30
September
Portugal
Troia, Portugal
Seabed Security, 30 September - 01 October 2025, Troia, Portugal
Seabed Security | 30 September - 01 October 2025 | Troia, Portugal Defence iQ Announces Inaugural Seabed Security...
23
September
United Kingdom
London, UK
Countering Explosive Threat & Demining conference, September 23 - 24, 2025, London, UK
Countering Explosive Threat & Demining conference | September 23 - 24, 2025 | London, UK The Countering Explosive...
View All Events